Robert Bradway, Amgen CEO (Reuters/Stephen Lam)
May 17, 2023 11:57 AM EDT
Deals
Law

Am­gen's CEO says he's 'con­fi­den­t' their $28B deal with Hori­zon can close de­spite FTC law­suit

Drew Armstrong

Executive Editor

A day af­ter fed­er­al an­titrust au­thor­i­ties sued to stop Am­gen’s $28 bil­lion takeover of Hori­zon Ther­a­peu­tics, Am­gen’s CEO said he still ex­pects the deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times